AFC
JBIO

Ares Financial Consulting’s Jade Biosciences JBIO Stock Holding History

Ares Financial Consulting’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444 Buy
+20
New +$417 ﹤0.01% 1092

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ares Financial Consulting's JBIO Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Jade Biosciences (JBIO) in Q2 2026: 20 shares worth $444. The stake represents ﹤0.01% of the portfolio and ranks #1092 among its holdings.

154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Ares Financial Consulting held 20 shares of Jade Biosciences worth $444 as of Q2 2026.
  • Jade Biosciences was a new Ares Financial Consulting position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1092 holding.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.